Company

Esanex

As of the edition of 20 October 2026, Esanex runs 1 drug; it is on route A at 2 targets and on route B at 0 targets.

Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.

Drugs by status

StatusCount
Stopped1
Total1

Where it needs a new molecule

Route A at 2 targets, route B at 0 targets.

Three of its 2 rows, by target and route
TargetRoute
HSP90AB1 Heat shock protein HSP 90-betaRoute A
HSP90AA1 Heat shock protein HSP 90-alphaRoute A

All 2 rows on route A or B

In the product

2 company-target rows on route A or B; 0 are not shown here, and no score is.

Where its trials are

  • Cancer: 11 trials led
  • Blood and lymph: 4 trials led
  • Immune system: 2 trials led